CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akesis Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akesis Pharmaceuticals Inc
888 Prospect St Ste 320
Phone: (858) 646-0789p:858 646-0789 LA JOLLA, CA  92037-4262  United States Fax: (803) 831-1494f:803 831-1494
On 12/27/2013, the Company's Chapter 7 Bankruptcy case (#09-10330) was closed in the U.S. Bankruptcy Court for the District of Delaware (Delaware)
On 4/22/2015, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Akesis Pharmaceuticals Inc for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Akesis Pharmaceuticals, Inc. is a contract research organization focusing on clinical research services and regulatory affairs consulting. The Company provides services in dermatological, ophthalmic, and topical products for a variety of indications. It serves the biotechnology, device, formulation development, generic, and pharmaceutical industries. The Company has been a part of more than 60 dermatology, ophthalmic, and topical development programs. The Company develops pharmaceutical development services including: Project and Program Management, Oversight and Conduct of Phase I-IV Trials, Clinical Trial Monitoring, Feasibility and Protocol Development, Site Identification and Selection, Patient Recruitment Support, Regulatory Document Management, 510k Planning and Application Preparation, GLP/GCP/GMP Auditing and Abbreviated New Drug Application (ANDA) and NDA Submission Preparation.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200812/31/2007YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JayLichter 51 11/3/2008 10/3/2006
President, Chief Executive Officer, Chief Operating Officer, Director CarlLeBel 51 11/3/2008 12/14/2007
Chief Financial Officer, Secretary John T.Hendrick 60 12/1/2004 12/1/2004
Director Kevin J.Kinsella 65 1/1/2004 1/1/2004
Director Kevin R.Sayer 56 1/24/2005 1/24/2005

General Information
Number of Employees: 2 (As of 12/31/2007)
Outstanding Shares: 24,933,826 (As of 10/31/2008)
Shareholders: 398
Stock Exchange: OTC
Federal Tax Id: 841409219
Fax Number: (803) 831-1494
Email Address: info@libertymint.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023